Sector
PharmaceuticalsOpen
₹1,213.05Prev. Close
₹1,223.35Turnover(Lac.)
₹6,743.96Day's High
₹1,254Day's Low
₹1,209.152 Week's High
₹1,31152 Week's Low
₹716.95Book Value
₹335.43Face Value
₹2Mkt Cap (₹ Cr.)
21,922.15P/E
16.78EPS
72.95Divi. Yield
0.785 Sep 2023
12:00 AM
BookCloser
14 Feb 2024
12:00 AM
Dividend
Dividend Amount: 1.25
Record Date: 26 Feb, 2024
5 Sep 2023
12:00 AM
AGM
Announcement Date: 05 Sep, 2023
9 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 36.5 | 36.5 | 36.5 | 36.4 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 4,665.5 | 4,155.4 | 4,054.6 | 3,833.1 |
Net Worth | 4,702 | 4,191.9 | 4,091.1 | 3,869.5 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 1,653.5 | 1,790.2 | 2,091.3 | 1,958 |
yoy growth (%) | -7.63 | -14.39 | 6.8 | 84.85 |
Raw materials | -500 | -397 | -388.5 | -572.8 |
As % of sales | 30.23 | 22.17 | 18.57 | 29.25 |
Employee costs | -380 | -356.1 | -312.2 | -232.1 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 392.2 | 583.1 | 887.6 | 634.1 |
Depreciation | -115.2 | -98.1 | -65.5 | -53.6 |
Tax paid | -82.7 | -108.6 | -189.4 | -139.3 |
Working capital | -24.9 | 273.2 | 977.8 | 236.8 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -7.63 | -14.39 | 6.8 | 84.85 |
Op profit growth | -27.75 | -37.74 | 34.16 | 146.52 |
EBIT growth | -33.16 | -33.09 | 38.47 | 167.7 |
Net profit growth | -34.77 | -32.03 | 41.1 | 180.33 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 3,998.8 | 2,707.1 | 1,944.8 | 2,052.1 | 1,915 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 3,998.8 | 2,707.1 | 1,944.8 | 2,052.1 | 1,915 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 128.1 | 104.6 | 99 | 103.6 | 107.4 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.65 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,519.8 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.5 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.45 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,636 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
V C Nannapaneni
Chairman & Independent Directo
G S Murthy
Director & Chief Executive Off
Rajeev Nannapaneni
Non-Exec. & Independent Dir.
T V Rao
Non-Exec. & Independent Dir.
D G Prasad
Non-Exec. & Independent Dir.
Leelaa Digumarti
Vice President & Director
PSRK Prasad
Non-Exec. & Independent Dir.
MUR Naidu
President & Director
D Linga Rao
Vice President & Director
Pavan Bhat
Company Sec. & Compli. Officer
Venkat Ramesh
Independent Director
A D Murthy Chavali
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Natco Pharma Ltd
Summary
Natco Pharma Limited is a vertically integrated and R&D focused pharmaceutical company that specialises in development, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs). The Companys focus is primarily on niche therapeutic areas and complex products. It sells products in over 40 countries. FDF products are sold in the United States, India, Europe and the rest of the world (RoW). Natcos API products are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets such as Brazil, Europe and USA. In the API segment, Natco has capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides.Natco Pharma is also engaged in contract manufacturing business, whereby the company undertakes selected contracts with pharmaceutical companies to manufacture and supply pharmaceutical products.Natco Pharma was originally incorporated on 19 September 1981 as private limited company under the name of Natco Fine Pharmaceuticals Private Limited. It became a deemed public company with effect from 1 July 1992. The name of the company was changed to Natco Pharma Limited and a fresh certificate of incorporation consequent upon change of name was issued by the RoC, Andhra Pradesh on 18 February 1993. The company was converted into a public limited company and a fresh certificate of incorporation dated
Read More
What is the Natco Pharma Ltd share price today?
The Natco Pharma Ltd shares price on N/A is Rs.₹1224.1 today.
What is the Market Cap of Natco Pharma Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Natco Pharma Ltd is ₹21924.84 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Natco Pharma Ltd?
The PE and PB ratios of Natco Pharma Ltd is 16.78 and 3.92 as of 22 Jul ‘24
What is the 52 Week High and Low of Natco Pharma Ltd?
The 52-week high/low is the highest and lowest price at which a Natco Pharma Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Natco Pharma Ltd is ₹714.65 and ₹1311 as of 22 Jul ‘24
What is the CAGR of Natco Pharma Ltd?
Natco Pharma Ltd's CAGR for 5 Years at 19.41%, 3 Years at 3.96%, 1 Year at 71.30%, 6 Month at 46.63%, 3 Month at 22.60% and 1 Month at 4.45%.
What is the shareholding pattern of Natco Pharma Ltd?
The shareholding pattern of Natco Pharma Ltd is as follows:
Promoters - 49.71 %
Institutions - 25.32 %
Public - 24.97 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
